FibroBiologics, Inc.

Fibrobiologics, Inc.

Biotechnology • Healthcare • Houston, TX, United States • FBLG (NCM)

FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications. The company was founded in 2021 and is based in Houston, Texas.

281 651 5150 455 East Medical Center Boulevard, Houston, TX 77598, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Layoff Events
Earnings Calls
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Earnings Call Transcripts

View All →
Q4 2025 Positive
Nov 19, 2025

FibroBiologics, Inc. (FBLG) secured approximately $4.0 million in gross proceeds through a Registered Direct Offering, paid for with sovereign-issued gold coins. The company simultaneously redeemed a $3.4 million convertible note, significantly reducing its debt burden. This strategic financing aims to bolster corporate liquidity and satisfy existing debt.

Recent News

FibroBiologics (FBLG) Rating Maintained as "Buy" by D. Boral Cap - GuruFocus
GuruFocus • Jan 6
FibroBiologics stock maintains Buy rating at H.C. Wainwright on psoriasis IND filing - Investing.com Nigeria
Investing.com Nigeria • Jan 2
$FBLG stock is down 31% today. Here's what we see in our data. - Quiver Quantitative
Quiver Quantitative • Dec 15
Biotech targeting chronic diseases raises $1.7M in stock sale - Stock Titan
Stock Titan • Dec 16
FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewswire
GlobeNewswire • Dec 15

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has FibroBiologics, Inc. had layoffs?
No layoff events have been recorded for FibroBiologics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does FibroBiologics, Inc. have?
FibroBiologics, Inc. has approximately 13 employees.
What industry is FibroBiologics, Inc. in?
FibroBiologics, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is FibroBiologics, Inc. a publicly traded company?
Yes, FibroBiologics, Inc. is publicly traded under the ticker symbol FBLG on the NCM. The company has a market capitalization of approximately $0.02 billion.
Where is FibroBiologics, Inc. headquartered?
FibroBiologics, Inc. is headquartered in Houston, TX, United States at 455 East Medical Center Boulevard, Houston, TX 77598, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.